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ORIGINAL ARTICLE
Lymph node metastases and elevated postoperative calcitonin:
Predictors of poor survival in medullary thyroid carcinoma
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JOHANNA LOUHIMO1, JOHANNA AROLA2* & CAJ HAGLUND1,4*
1Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Department of
Pathology, Haartman Institute and HUSLab, University of Helsinki and Helsinki University Hospital, Helsinki,
Finland, 3Department of Oncology, Helsinki University Hospital, Helsinki, Finland, and 4Research Programs Unit,
Translational Cancer Biology, University of Helsinki, Finland.
ABSTRACT
Background. Total thyroidectomy is the treatment of choice for medullary thyroid carcinoma (MTC), but the
extent of neck dissection is controversial. Lymph node metastases, distant metastases, and old age are known
predictors of poor survival.
Patients. Patients treated for primary MTC at Helsinki University Hospital from 1990 to 2009 were included
(n¼ 54). Their clinical characteristics, treatment, and outcome were analysed retrospectively, these patients were
followed until death or their last follow-up date.
Results. At last follow-up (3.4–23 years), of 54 MTC patients, 19 (35%) were disease-free, 17 (32%) were alive
with disease, and 12 (22%) had died of MTC; six patients died of unrelated causes (11%). All disease-free patients
were node negative and had normal postoperative calcitonin level. Of 19 disease-free patients, only four (21%)
had undergone lymph node dissection. All patients who died of MTC were Stage IV at diagnosis and died with
distant metastases. Disease-specific five–and 10-year survival was 84% and 76.2%. Advanced T-stage (p¼ 0.004),
lymph node metastases (p50.001), distant metastases (p50.001), stage (p50.001), and elevated postoperative
calcitonin (p50.001) significantly associated with survival.
Conclusions. Lymph node metastasis and elevated postoperative calcitonin are important prognostic factors.
Patients with lymph node metastasis and/or elevated postoperative calcitonin with present treatments cannot
become disease-free, but most of them can live a long life with metastasis.
Medullary thyroid carcinoma (MTC) is a rare
malignancy originating from calcitonin secreting
parafollicular C-cells. One of four patients with
MTC has a hereditary aetiology: either familial
MTC or multiple endocrine neoplasia (MEN) type
2A or 2B [1]. MTC has a varying clinical course, but
the average 10-year survival is 75–80% [2]. As
calcitonin serves as a sensitive tumour marker after
primary surgery, normal postoperative calcitonin
predicts cure. The clinical course of those with
elevated postoperative calcitonin varies markedly:
from rapid progression with survival of only a few
years to stable disease lasting decades.
For MTC, the recommend surgery has been total
thyroidectomy and central neck dissection [3–5].
The need for lateral neck dissection is controversial,
with poor efficacy of non-surgical treatments pre-
senting a problem. MTC cells do not concentrate
radioactive iodine, and the effect of chemotherapy is
limited [6]. For lymph node recurrence, most
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family history. Surgical treatment was lobectomy or
thyroidectomy. Extent of lymph node dissection was
determined as none, limited (central and/or lateral
‘‘node picking’’) or selective neck dissection [14].
Definition of stage was done according to the UICC
TNM classification [15], and primary lymph node
status was considered as N1 (pN1) when positive
lymph nodes were found in histological examination
and, as N0 when no lymph nodes were evident with
ultrasound, during surgery, or in histological exam-
ination. Only four N0 patients underwent lymph
node dissection, therefore, N0, in most cases,
represented clinical N0. The diagnosis of local
recurrence was made clinically by ultrasound or
other imaging techniques, or by elevated calcitonin
level.
All patients were followed until death or until the
last follow-up date (April 2013). Follow-up time was
3.4–23 years. Survival data came from the
Population Register and the cause of death from
patient records and from Statistics Finland. The
end-points of the study were either death from MTC
or tumour status at the time of the last follow-up
date (disease-free, alive with disease either biochem-
ically active, or distant metastases). Patients with no
clinical or radiological signs of disease and normal
calcitonin level at last follow-up were considered to
be disease-free. Approval of the study came from the
local Ethnics Committee and National Supervisory
Authority of Welfare and Health (226/E6/2006;
revised version approved 17 April 2013).
Laboratory assays
During the time period three assays were used
for calcitonin measurement: LIAISON immunoana-
lysator (BYK, Sangtec), commercial immunolumi-
nometric assay (ELISA, Immuno-Biological
Laboratories, Ibl, Hamburg, Deutschland) and
chemiluminescent assay Immulite 2000
(Immunoluminometric assay, CLIA, Siemens
Healthcare Diagnostics, Marburg, Germany).
Correlation between the first two is quite good
(r¼0.93) and between the last two good (r¼0.99).
Normal calcitonin values for men were53.3 pmol/L
and for women 1.5 pmol/L (LIAISON), and 53.8
pmol/L and 1.7 pmol/L (ELISA and Immulite 2000).
Statistics
Statistical analysis was performed with SPSS soft-
ware (IBM SPSS Statistics 20.0), with p-values less
than 0.05 regarded as statistically significant.
Association of patient characteristics with nodal
status, extent of lymph node dissection, follow-up
status, and postoperative calcitonin level was
assessed with the 2-test (or Fisher’s exact test
when applicable). The Mann-Whitney U-test or
Kruskall-Wallis test served to determine the signifi-
cance of the difference in age, tumour size, and
postoperative calcitonin value between patient
groups. Life tables and survival curves were calcu-
lated by the Kaplan-Meier method. The log-rank
test was applied to test the significance of associ-
ations between survival and age, gender, nodal
metastases, distant metastases, stage, and post-
operative calcitonin level. Patients alive at the end
of follow-up and those who died from unrelated
causes were censored.
Results
According to the Finnish Cancer Registry, 203
MTCs were diagnosed in Finland (population
approx. 5 million) during the 20-year period from
1990 to 2009. Of these, 54 patients were treated at
Helsinki University Hospital, and were included in
our study. Two autopsy cases were excluded, due to
their occult MTC. Median follow-up time was 11.8
years (range 3.4–23.2 years) for patients alive at the
end of the study, and 3.9 years (range 0.04–16.9
years) for patients who died of MTC.
Symptoms and diagnosis
The most common symptom and finding was
thyroid nodule (34/54, 63%), followed by diarrhoea
(4/54, 7%).
Fine needle aspiration biopsy (FNAB) of the
primary tumour was performed on 44 patients
(81%). Of these 44, cytology classified 16 nodules
as MTC, six as carcinoma NOS, 11 as neoplastic,
nine as non-neoplastic, and two as non-diagnostic.
Eleven patients with non-neoplastic/non-diagnostic
FNAB underwent surgery for following reasons:
solitary nodule (5), diarrhoea with elevated calci-
tonin (suspicion of MTC) (1), goitre (4), or MTC
histology from a lymph-node metastases (1). Final
MTC diagnosis was confirmed by histology and
calcitonin immunohistochemistry of the surgical
specimen.
Ten MTC patients did not undergo FNAB. Of
these 10, five patients with MEN syndrome under-
went prophylactic thyroidectomy, two patients
underwent thyroid surgery for a goitre, and one for
Basedow’s disease. In two patients thyroidectomy
was performed for a thyroid nodule found at surgery
for HPT.
DNA testing was performed on 52 patients; eight
were positive for RET proto-oncogene. The two
patients without RET testing had metastatic MTC
and died soon after the diagnosis. One died of MTC

































and the other of intracerebral bleeding. These two
were classified as sporadic by a negative family
history.
Clinical characteristics and follow-up
At the end of the follow-up, 19 patients (35%) were
disease-free, and 12 (22%) had died of MTC.
Disease-specific five- and 10-year survival was 84%
and 76.2%. Mean survival was 18.2 years, and at the
end of our study, the final disease-specific survival
was 69.3%. Most neck recurrences were detected
soon after the primary operation, within a median of
one year. In four patients, the neck recurrence was
detectable more than five years after the initial
operation, even as late as at 18 years. Late distant
metastases were detectable within median of three
years after the primary operation (range 1.7–5.9
years).
Clinical characteristics of MTC patients are
summarised in Tables I and II. Characteristics
varied a great deal between the three patient
groups (disease-free, alive with disease, died of
MTC). In short, 19 (35%) disease-free patients
had neither lymph node nor distant metastases, and
their postoperative calcitonin levels were normal.
In contrast, all patients who died of MTC had stage
IV disease (presence of thyroid capsule invasion,
lymph node metastases further than pre- and
paratracheal, or distant metastases), and also ele-
vated postoperative calcitonin.
Distant metastases
At diagnosis of the 54, nine patients (17%) had
distant metastases, and another nine developed them
later. The most common sites were liver (83%),
bone (56%), and lungs (33%), whereas rare loca-
tions were the mediastinum, eye, ovary, brain,
adrenal gland, and pancreas.
MEN syndrome
Eight patients (15%) had MEN syndrome
(7 MEN2a, 1 MEN2b); their mean age was 40
(median 38.9 years); only one of them was female.
Their tumours were small (mean 1.6 cm, median
0.7 cm, range 0.3–7 cm) and usually multifocal (7/8,
88%). Only one patient had lymph node metastases
and none distant metastases. Moreover, one patient
had local recurrence. All MEN patients were alive at
the end of follow-up (range 4.2–22.1 years); five
Table I. Clinical characteristics of MTC patients: disease-free (19), alive with disease (17) and dead from medullary thyroid cancer (12).
Six patients who died from unrelated causes (pneumonia 2, shooting accident 1, intracerebral haematoma 1, metastatic colon cancer 1, and
obstructive bronchitis 1) and were excluded. Tumour-Node-Metastases (TNM) stage was assessed according to the international Union









from MTC n (%) p-Value
6 dead for
other reasons
Median age (years) 47 41 47 48 ns 67
Women 27 (50) 14 (74) 8 (47) 4 (33) 1
Men 27 (50) 5 (26) 9 (53) 8 (67) ns 5
Sporadic 46 (85) 14 (74) 14 (82) 12 (100) ns 6
Median tumour size (cm) 2.0 1.5 3.0 2.6 ns 2.8
Extent of tumour
T1 26 (35) 15 (79) 6 (35) 3 (25) 1
T2 8 (15) 3 (16) 2 (12) 1 (8) 50.001 2
T3 7 (13) 1 (5) 5 (29) 1 (8) 0
T4 13 (24) 0 4 (24) 7 (59) 2
UICC stage
Stage I 19 (35) 15 (79) 3 (18) 0 1
Stage II 8 (15) 4 (21) 4 (23) 0 50.001 0
Stage III 3 (6) 0 3 (18) 0 0
Stage IV 24 (44) 0 7 (41) 12 (100) 5
Multifocal tumour 11 (20) 4 (21) 4 (24) 3 (23) ns 0
Nodal metastases 24 (44) 0 9 (53) 10 (83) 50.001 5
Neck recurrence 21 (40) 0 13 (76) 7 (58) 50.001 1
Distant metastases 18 (33) 0 4 (24) 12 (100) 2
– Primary distant metastases 9 (17) 0 1 6 50.001 2
– Late distant metastases 9 (17) 0 3 6 50.001 0
Normal post op calcitonin (yes) 21 (39) 19 (100) 2 (12) 0 50.001 0
Postoperative calcitonin (median) 0 36 1350 50.001 705
Last calcitonin value (median) 0 47 6779 50.001 2799
Lymph node dissection
– No dissection 15 2 1 2
– Limited 4 7 7 50.001 3
– Selective 0 8 4 1
*In one MEN patient, MTC focus was very small (0.3 cm) and treatment was lobectomy alone.

































were disease-free, and three had biochemically active
disease. In addition to thyroid surgery, seven patients
underwent surgery for pheochromocytoma, and four
for hyperparathyroidism.
Surgical treatment
Thyroid surgery was performed on 52 patients: total
thyroidectomy on 37 patients (71%), and lobectomy
at primary operation followed by removal of the
other lobe at secondary operation for 14 patients
(27%). One microcarcinoma patient underwent
lobectomy only. Two patients were inoperable and
died soon after the diagnosis.
Of the 52 operated patients, 12 patients (23%)
underwent selective neck dissection, and 21 patients
(40%) limited neck dissection; in 19 (37%) no neck
dissection was performed, and these were clinically
N0. Enlarged mediastinal lymph nodes were dis-
sected in two patients. Furthermore, 21 (39%)
underwent lymph node dissection for neck recur-
rence, and five underwent surgery for metastases
[mediastinum (2), lung and brain (1), liver (1),
ovary (1)].
Thirty patients underwent only surgery and did
not receive any other treatments. Of these 30
patients, 24 underwent only primary thyroid surgery
(± lymph node excision), and this group included
the 19 patients who were disease-free at the end of
the follow-up (range 3.4–23.1 years). Six patients
underwent primary thyroid surgery and later on re-
operation for neck recurrence.
Table I shows the extent of lymph node dissection
in MTC patient groups. Most patients (15/19) who
were disease-free at the end of the follow-up under-
went no dissection. All patients who underwent
selective neck dissection were either alive with
disease or dead of MTC.
Other treatments
Radiotherapy and/or medical treatment was admini-
strated to 22 of the 54 patients: 20 patients received
radiotherapy (six of them primary radiotherapy),
eight chemotherapy, two radionuclide-therapy, eight
somatostatin, and five tyrosine-kinase inhibitor treat-
ment. Majority of these 22 patients (19), were at
advanced stage of the disease and most of them have
died (14).
Of the patients receiving tyrosine-kinase inhibitor
(5), two have died of MTC; one had no response
and the other partial response for one year. At the
end of the follow-up, three were alive with metas-
tases; one was progression-free after two years of
treatment with sorafenib, and the other two have had
a partial response.
Calcitonin level
Of the 54, postoperative calcitonin was normal in 21
(39%), of whom, 19 (90%) were disease-free at the
end of the follow-up. Patients with elevated calci-
tonin level were significantly more often men
(p¼ 0.011), had lymph node (p50.001) and distant
metastases (p¼ 0.033), were stage IV (p50.001),
and had more neck (p50.001) and distal recur-
rences (p¼ 0.007). Postoperative and latest calci-
tonin levels differed between the three survival
groups (disease-free, alive with metastases, died of
MTC); calcitonin level was highest in the last group
(p50.001) (Table I).
As to individual postoperative calcitonin levels,
these were: in disease-free patients (0), in those
alive with disease, a median 36 (range 0–2800), and
in patients who died of MTC, a median 1350
(range 26–20 362). Postoperative calcitonin level
was significantly higher in patients who died of
Table II. Details of 12 patients who died of medullary thyroid cancer. All were stage IV, with sporadic disease. All underwent
thyroidectomy, except Patient 1, who died soon after diagnosis. At the end, all patients had distant metastases. T-classification was assessed



















1 36/F 0.08 X T4N1M1 none 2195
2 36/F 0.7 3 T2N1M1 RT, T 1 Sternotomy* 96 257
3 69/F 1.4 0.3 T1N0M1 S 4500 35 000
4 53/M 2 2.2 T4N1M1 CH 1350 4412
5 53/M 3.1 0.9 T4N1M1 RT, CH, S 20 362 91 000
6 75/M 3.3 7.5 T4N0M0 RT, S 2 1740 9146
7 55/M 4.5 1.8 T1N1M0 RT, CH 5 26 505
8 47/M 4.7 4 T4N1M1 RT, CH, S 410 1700
9 49/M 5.9 X T4N1M0 RT, S 6 1400 20 832
10 38/M 6.5 4 T3N1M0 RT, CH, S 5 Sternotomy 106 73 700
11 17/F 9.2 3.7 T4N1M0 RT, CH, S 3 Ovary 1400 144 000
12 45/M 16.9 1.6 T1N1M0 RT, T, S 4 Lung, brain 58 276
CH, chemotherapy; CTN, calcitonin, values pmol/L; DM, distant metastasis; oper, operation; RT, radiotherapy; S, somatostatin; T,
tyrosine kinase inhibitor.
*Mediastinal and cervical lymph nodes operated on.

































MTC than in those alive with disease (p¼ 0.004)
(Figure 2).
Prognostic factors and survival
Advanced T-stage (p¼ 0.004), lymph node metas-
tases, distant metastases, stage, and elevated post-
operative calcitonin (all p50.001) were factors for
worse prognosis. Age, gender, or type of MTC
(sporadic MTC, MEN syndrome) lacked signifi-
cance for prognosis. N1 patients were significantly
more often men (p¼ 0.006), had larger tumours
(p¼ 0.037), more often neck recurrences (p¼ 0.009)
and distant metastases (p50.001).
The five- and 10-year survival for stage I patients
was 100% and 100%, and for stage IV 62.8% and
44.9%. For women the five- and 10-year survival
was 88.6% and 83.1%, and for men 78.7% and
68.2%. The corresponding figures for N1 patients
were 72.3% and 53.5%, and for M1 patients 16.9%
and 16.9%. The Kaplan-Meier survival curves for
N0M0, N1M0, and N0-1M1 patients are presented
in Figure 1.
Discussion
MTC patients in our small consecutive series can
roughly be divided into three similar-sized groups:
one third cured after initial treatment (disease-free),
one third with recurrence or residual disease but
surviving (alive with disease), and one third dying
of MTC. The cured ones were easy to recognise.
They had no lymph node metastases and had normal
postoperative calcitonin levels. Moderate- and high-
risk patients had either slow progression rate with
fairly good survival, or rapid progression fast and
lethal disease.
All disease-free patients were clinically N0, with
normal postoperative calcitonin level. Postoperative
calcitonin level has been shown to be a significant
indicator of recurrence-free survival [16,17].
Patients with biochemical remission after primary
treatment have an only 3% risk of recurrence [18].
Accordingly, in our study as well, all but two patients
with normal postoperative calcitonin (90%) were
disease-free at the end of the follow-up. Normal
postoperative calcitonin level, however, did not
guarantee disease-free survival, nor did N0 stage
alone; two N0 patients died of MTC, and eight had
recurrence. Postoperative calcitonin was high in both
of the N0 patients who died of MTC and was also
high in most N0 patients with recurrences (6/8).
Clinical N0 in this study, however, is biased, because
it was based on a clinical and radiological evaluation
of lymph node status, therefore it is likely that some
early metastases are missed. Based on our results,
negative lymph node status and normal postopera-
tive calcitonin level in combination are best pre-
dictors for recurrence-free survival.
The ‘‘alive with disease’’ group was heteroge-
neous, including patients at all stages. In this
particular patient group, predicting tumour behav-
iour is very difficult. Most patients, 15 of 17, had
elevated postoperative calcitonin levels, but their
postoperative levels were lower than in those who
died of disease. Calcitonin levels, however,
Figure 1. Kaplan–Meier survival curves of 54 MTC patients
without metastases (N0M0), with lymph node metastases
(N1M0), and with distant metastases (N0-1M1). Differences in
survival between groups were significant (p50.001, log-rank test).
Figure 2. Postoperative calcitonin level (pmol/L) in three groups
(1¼disease-free, 2¼alive with disease, 3¼dead from medullary
thyroid carcinoma). Postoperative calcitonin levels were signifi-
cantly higher in patients who died of MTC compared to those
alive with disease (p¼0.004, Mann-Whitney U-test).

































overlapped, making reliable prediction of survival by
postoperative calcitonin level impossible, calcitonin
surely represents tumour load and thus reflects stage
[19,20]. Nevertheless, based on our results, we can
only suggest that an extremely high postoperative
calcitonin level of 10 000 means fatal disease.
Half of the patients in the ‘‘alive-with-disease’’
group had primary lymph node metastases. These
metastases impair survival, but their prognostic
significance for long-time survival remains contro-
versial. MTC patients with lymph node metastases
have shown more local recurrences and distant
metastases [21–23]. Biochemical remission is lower
among MTC node-positive than node-negative
patients [20,22]. Furthermore, in recurrent MTC,
biochemical cure (calcitonin normalisation) is rare,
described in only from 0% to 22% of cases [24–26].
In accordance with previous findings, we found that
patients with primary lymph node metastases and
those with recurrent MTC will not become disease-
free despite radical surgery, but they may have a long
life expectancy with biochemical disease or even with
distant metastases. Four of our patients were alive
with distant metastases (follow-up times 5.3, 6.7,
10.0, and 13.1 years), one of them surviving 13 years
with primary lung metastases. In rare cases, curative
surgical resection of local recurrence or of single
distant metastasis may be achieved.
All patients who died of MTC were Stage IV, and
their postoperative calcitonin levels were high, prob-
ably reflecting tumour load. None of the Stage I–III
patients died of MTC. Most of the deceased patients
had primary lymph node metastases, and half had
primary distant metastases. All of these patients
eventually developed distant metastases. M1 patients
had shorter survival than the patients who developed
metastases later (median survival 1.7 vs. 6.2 years).
Preoperative cytological diagnosing of MTC can
be challenging. Serum calcitonin is the most sensi-
tive diagnostic tool to confirm MTC in patients with
thyroid nodules [27]. In our series, as many as nine
of 44 (20%) FNAs were false negative as diagnosed
as non-neoplastic and also only 16/44 (36%) had
definitive diagnosis of MTC. In recent mega-
analysis, FNA sensitivity in MTC lesions ranged
between 12.5% and 88.2% and the key conclusion
was that only 56% of histologically proven MTCs
are correctly detected by FNA [28]. Elisei et al.
confirmed that calcitonin measurement is more
sensitive than FNA for the diagnosis of MTC by
screening 10 000 patients with nodular thyroid
diseases [29].
Primary lymph node status in MTC is an
important prognostic factor. The latest ATA guide-
lines recommend a total thyroidectomy and central
lymph node dissection for all MTC patients, and in
cases with MTC confined to the neck and cervical
lymph nodes, also resection of involved lateral
compartments [27]. If the basal calcitonin level is
greater than 200 pg/mL (734 pmol/L), contralateral
neck dissection should be considered as well [27].
In our study, disease-free patients had N0 disease,
and most of them did not undergo lymph node
dissection. However, as mentioned, clinical N0 is
rarely definitely N0. Our patient material with dates
from 1990 to 2009, and back then, performing
lymph node dissection in patients without enlarged
nodes with ultrasound or at operation was not
routine practice. Of 19 disease-free patients, only
four underwent limited lymph node dissection.
Thus, based on our small retrospective material, it
seems that lymph node dissection has no effect on
prognosis in patients without macroscopic lymph
node metastases. Furthermore, supporting our find-
ings, the Esfandiari group recently suggested that the
extent of lymph node dissection should be tailored to
tumour size and distant metastases. When evaluating
a cohort of 2968 MTC patients, they found that
N0M0 patients with tumours under 2 cm may do
well with total thyroidectomy only and no central
node dissection [30]. Further studies are warranted
to determine the effect of less extensive surgical
strategy on survival and on recurrence in low-risk
patients. However, because lymph node status pre-
dicts cure, central node dissection in such patients is
advisable in order to discover microscopical/histo-
logical lymph node status.
Lateral neck dissection is recommended for
lymph node metastases [27]. Lymph node dissection
does not provide complete cure, but patients
undergoing less extensive primary surgery require
more re-operations than patients undergoing total
thyroidectomy with cervical lymph node dissection
[6]. In the large patient series reported by Esfandiari,
more extensive surgery resulted in a significant
improvement in survival if tumours were 42.0 cm
and with existing distant metastases [30].
Although our series is small, clinical characteris-
tics are within the reported range. To our credit, our
clinical data and follow-up underwent thorough
analysis. All histological specimens were re-evaluated
by an endocrine pathologist and follow-up informa-
tion was available for all patients.
Of the MTC patients of our study, 35% were
disease-free at the end of the follow-up, in accord-
ance with other findings (33–37.5%) [17,31].
Incidence of lymph node metastasis varies between
27.9% and 63%; in our study it was 43% [2,17,
31–34]. Primary distant metastasis have occurred in
11–27% of cases [17,32,34]; our percentage was
17%. The gender distribution was equal in our
material; other studies have showed a small female

































predominance [2,19,35]. The mean age has varied
between 40 and 51 years [2,35,36]; in our study this
was 48. Survival ranges from 56% to 85% at 10
years: 78.4% in [17], 69% [37], 85% [34], 56%
[32], 69.2% [35], 73.7% [33]; in our study, 10-year
survival rate was 76%. Our MTC patients who died
from disease lived an average of 4.7 years (median
3.4 years), in other series from 3.6 to 4.5 years
[6,34]. Lymph node metastases, distant metastases,
and age over 65 at diagnosis have been shown to be
the strongest predictors of survival [2]. In our study,
gender did not associate with survival, but advanced
T-stage, lymph node metastases, and distant metas-
tases predicted poor survival. All MEN2 patients
are alive, but this lacks prognostic significance and
can be explained by low number of cases.
Conclusions
Primary lymph node status is an important prog-
nostic factor. We noticed that MTC patients with
lymph node metastasis would not be completely
disease-free, but could live a long life. In our small
consecutive series, we also found that most patients
who were disease-free at the end of the follow-up,
did not undergo lymph node dissection. We could
not, however, recommend less extensive surgery for
N0 patients. Even in cases where postoperative
calcitonin is normal, it is difficult to be sure that
MTC patient does not have lymph node metastasis.
Micrometastasis may still be present, and lymph
node dissection may decrease local recurrence and
prevent complications from repeated surgery.
Normal postoperative calcitonin is a strong indicator
of negative lymph nodes, but is it not a guarantee for
N0 status.
Declaration of interest: The authors report no
conflicts of interest. The authors alone are respon-
sible for the content and writing of the paper.
References
[1] Leboulleux S, Baudin E, Travagli JP, Schlumberger M.
Medullary thyroid carcinoma. Clin Endocrinol (Oxf)
2004;61:299–310.
[2] Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid
carcinoma: Demographic, clinical, and pathologic
predictors of survival in 1252 cases. Cancer 2006;107:
2134–42.
[3] Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI,
Sellin RV, et al. Surgical strategy for the treatment
of medullary thyroid carcinoma. Ann Surg 1999;230:
697–707.
[4] Moley JF, DeBenedetti MK. Patterns of nodal metastases in
palpable medullary thyroid carcinoma: Recommendations
for extent of node dissection. Ann Surg 1999;229:880–7;
discussion 887–8.
[5] Machens A, Hauptmann S, Dralle H. Prediction of lateral
lymph node metastases in medullary thyroid cancer. Br J
Surg 2008;95:586–91.
[6] Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark
OH. Medullary thyroid carcinoma: Clinical characteristics,
treatment, prognostic factors, and a comparison of staging
systems. Cancer 2000;88:1139–48.
[7] Moley JF, Dilley WG, DeBenedetti MK. Improved results
of cervical reoperation for medullary thyroid carcinoma.
Ann Surg 1997;225:734–40; discussion 740–3.
[8] Kebebew E, Kikuchi S, Duh QY, Clark OH. Long-term
results of reoperation and localizing studies in patients with
persistent or recurrent medullary thyroid cancer. Arch Surg
2000;135:895–901.
[9] Fialkowski E, DeBenedetti M, Moley J. Long-term out-
come of reoperations for medullary thyroid carcinoma.
World J Surg 2008;32:754–65.
[10] Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT,
Kell EM, et al. Phase II study of daily sunitinib in FDG-
PET-positive, iodine-refractory differentiated thyroid
cancer and metastatic medullary carcinoma of the thyroid
with functional imaging correlation. Clin Cancer Res
2010;16:5260–8.
[11] Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV,
Liang J, et al. Phase II clinical trial of sorafenib in metastatic
medullary thyroid cancer. J Clin Oncol 2010;28:2323–30.
[12] Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S,
Moon YJ, et al. Vandetanib for the treatment of symptom-
atic or progressive medullary thyroid cancer in patients with
unresectable locally advanced or metastatic disease: U.S.
Food and Drug Administration drug approval summary.
Clin Cancer Res 2012;18:3722–30.
[13] Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA,
Santoro M, et al. Vandetanib in patients with locally
advanced or metastatic medullary thyroid cancer: A
randomized, double-blind phase III trial. J Clin Oncol
2012;30:134–41.
[14] Ferlito A, Robbins KT, Shah JP, Medina JE, Silver CE, Al-
Tamimi S, et al. Proposal for a rational classification of neck
dissections. Head Neck 2011;33:445–50.
[15] Sobin LH, Wittekind C editor. UICC: TNM classification
of malignant tumors, 6th ed. New York: Wiley-Liss; 2002.
[16] Meijer JA, le Cessie S, van den Hout WB, Kievit J,
Schoones JW, Romijn JA, et al. Calcitonin and carcinoem-
bryonic antigen doubling times as prognostic factors in
medullary thyroid carcinoma: A structured meta-analysis.
Clin Endocrinol (Oxf) 2010;72:534–42.
[17] Modigliani E, Cohen R, Campos JM, Conte-Devolx B,
Maes B, Boneu A, et al. Prognostic factors for survival and
for biochemical cure in medullary thyroid carcinoma:
Results in 899 patients. The GETC Study Group.
Groupe d’etude des tumeurs a calcitonine. Clin
Endocrinol (Oxf) 1998;48:265–73.
[18] Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat
A, et al. Complete surgical lymph node resection does not
prevent authentic recurrences of medullary thyroid carcin-
oma. Clin Endocrinol (Oxf) 2001;55:403–9.
[19] Cohen R, Campos JM, Salaun C, Heshmati HM, Kraimps
JL, Proye C, et al. Preoperative calcitonin levels are
predictive of tumor size and postoperative calcitonin nor-
malization in medullary thyroid carcinoma. Groupe
d’Etudes des Tumeurs a Calcitonine (GETC). J Clin
Endocrinol Metab 2000;85:919–22.
[20] Machens A, Schneyer U, Holzhausen HJ, Dralle H.
Prospects of remission in medullary thyroid carcinoma
according to basal calcitonin level. J Clin Endocrinol Metab
2005;90:2029–34.

































[21] Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann
M, Hinz U, Ziegler R, et al. Impact of modified radical neck
dissection on biochemical cure in medullary thyroid car-
cinomas. Surgery 2001;130:1044–9.
[22] Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N,
Leboulleux S, et al. Rationale for central and bilateral
lymph node dissection in sporadic and hereditary medullary
thyroid cancer. J Clin Endocrinol Metab 2003;88:2070–5.
[23] Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U,
Dralle H. Improved prediction of calcitonin normalization
in medullary thyroid carcinoma patients by quantitative
lymph node analysis. Cancer 2000;88:1909–15.
[24] Gimm O, Ukkat J, Dralle H. Determinative factors of
biochemical cure after primary and reoperative surgery for
sporadic medullary thyroid carcinoma. World J Surg
1998;22:562–7; discussion 567–8.
[25] Marzano LA, Porcelli A, Biondi B, Lupoli G, Delrio P,
Lombardi G, et al. Surgical management and follow-up of
medullary thyroid carcinoma. J Surg Oncol 1995;59:162–8.
[26] van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM.
Long-term course of patients with persistent hypercalcito-
ninemia after apparent curative primary surgery for medul-
lary thyroid carcinoma. Ann Surg 1990;212:395–400;
discussion 400–1.
[27] Wells SA, Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel
RF, et al. Revised American Thyroid Association guidelines
for the management of medullary thyroid carcinoma. The
American Thyroid Association Guidelines Task Force on
medullary thyroid carcinoma. Thyroid 2015;25:567–610.
[28] Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G,
Valabrega S, et al. Detection rate of FNA cytology in
medullary thyroid carcinoma: A meta-analysis. Clin
Endocrinol (Oxf) 2015;82:280–5.
[29] Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C,
Grasso L, et al. Impact of routine measurement of serum
calcitonin on the diagnosis and outcome of medullary
thyroid cancer: Experience in 10,864 patients with nodu-
lar thyroid disorders. J Clin Endocrinol Metab 2004;
89:163–8.
[30] Esfandiari NH, Hughes DT, Yin H, Banerjee M, Haymart
MR. The effect of extent of surgery and number of
lymph node metastases on overall survival in patients with
medullary thyroid cancer. J Clin Endocrinol Metab
2014;99:448–54.
[31] Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C. Long-
term prognosis of medullary thyroid carcinoma. Clin
Endocrinol (Oxf) 2008;69:497–505.
[32] Hyer SL, Vini L, A’Hern R, Harmer C. Medullary thyroid
cancer: Multivariate analysis of prognostic factors influen-
cing survival. Eur J Surg Oncol 2000;26:686–90.
[33] Bhattacharyya N. A population-based analysis of survival
factors in differentiated and medullary thyroid carcinoma.
Otolaryngol Head Neck Surg 2003;128:115–23.
[34] Grozinsky-Glasberg S, Benbassat CA, Tsvetov G,
Feinmesser R, Peretz H, Shimon I, et al. Medullary thyroid
cancer: A retrospective analysis of a cohort treated at a
single tertiary care center between 1970 and 2005. Thyroid
2007;17:549–56.
[35] Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up
of patients with medullary carcinoma of the thyroid. Cancer
1997;79:132–8.
[36] Machens A, Hofmann C, Hauptmann S, Dralle H.
Locoregional recurrence and death from medullary thyroid
carcinoma in a contemporaneous series: 5-year results. Eur
J Endocrinol 2007;157:85–93.
[37] Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ,
Goellner JR, Grant CS, et al. Medullary thyroid carcinoma:
Clinicopathologic features and long-term follow-up of 65
patients treated during 1946 through 1970. Mayo Clin Proc
1992;67:934–40.
364 P. Siironen et al.
D
ow
nl
oa
de
d 
by
 [
U
ni
ve
rs
ity
 o
f 
H
el
si
nk
i]
 a
t 0
0:
16
 0
4 
A
pr
il 
20
16
 
